ClinicalTrials.gg
Status unknownNCT05249153DEXUpdated Nov 21, 2024

Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery

An interventional study of low dose of dexmedetomidine with sufentanil and high dose of dexmedetomidine with sufentanil in Dexmedetomidine, sponsored by Peking Union Medical College Hospital. Status unknown at 1 site in China. Open to participants aged 1 Year to 14 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2024), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Sep 2020, registered Jan 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
1 Year to 14 Years
Sex
All
01

Study summary

The primary purpose of this three-arm single center, randomized, subject and assessor blind, controlled clinical study is to evaluate the effect of dexmedetomidine on patient-controlled intravenous analgesia after pediatric scoliosis orthopedics.

Read the detailed description

The study is a single center, randomized, subject and assessor blinded, controlled clinical study.

Children who meet the inclusion/exclusion criteria will be evaluated. The patients will use a postoperative analgesic pump which is named as patient-control-analgesia (PCA) until the end of surgery with different dose of drugs. The control group will be set as using sufentanil only (0.05ug/kg/h infusion and 0.05ug/kg bolus). The experimental group will use sufentanil combined with different doses of dexmedetomidine. Low dose of dexmedetomidine PCA formula is 0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion and 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus. High dose of dexmedetomidine PCA formula is 0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion and 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus.

Then patients will be followed until they discharge.

The purpose of this trial is to evaluate the effect of of dexmedetomidine on patient-controlled intravenous analgesia after pediatric scoliosis orthopedics.

02

Conditions studied

  • Dexmedetomidine

Keywords

  • dexmedetomidine
  • pediatric anesthesia
  • patient-control analgesia
  • scoliosis orthopedics
03

In context

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,148 studies on the registry; 473 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 1-14 years scheduled to receive scoliosis orthopedics under general anesthesia;
  • Weight is ±15% of standard weight (standard weight (kg) = height (cm) -100);
  • Informed consent signed.

Exclusion criteria

Exclusion Criteria:

  • Allergy to dexmedetomidine;
  • Obvious abnormalities of heart, lung, liver, renal function and endocrine function;
  • Patients who can not cooperate with this trial.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • No intervention
    Sufen

    PCIA: continue with 0.05ug/kg/h sufentanil, 0.05ug/kg sufentainil bolus

  • Experimental
    Sufen with low DEX

    PCIA: continue with 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine bolus

    Drug: low dose of dexmedetomidine with sufentanil

  • Experimental
    Sufen with high DEX

    PCIA: continue with 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine bolus

    Drug: high dose of dexmedetomidine with sufentanil

Interventions

  • Druglow dose of dexmedetomidine with sufentanil

    low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)

    Also known as: Sufen with low DEX

  • Drughigh dose of dexmedetomidine with sufentanil

    high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)

    Also known as: Sufen with high DEX

06

What researchers measure

Primary outcomes

  1. Postoperative opioid analgesic dosage

    the total opioid consumption in PCIA postoperatively

    Time frame: 48 hours postoperatively

Secondary outcomes

  1. Intraoperative opioid analgesic dosage

    Intraoperative opioid analgesic dosage

    Time frame: Intraoperative

  2. Effective pressing times of PCIA

    extract the data from the electric analgesic pump

    Time frame: 48 hours postoperatively

  3. Total pressing times of PCIA

    extract the data from the electric analgesic pump

    Time frame: 48 hours postoperatively

  4. Remedial analgesics dosage

    extract the data from the followup

    Time frame: 48 hours postoperatively

  5. postoperative pain

    using VAS method to evaluate pain status. 0 score refers to comfort, 10 score refers to excruciating pain. Higher scores mean a worse outcome.

    Time frame: 48 hours postoperatively

  6. LOS

    the length of stay

    Time frame: through study completion, an average of 7 days postoperatively.

  7. Patient satisfaction

    patients' and relatives' satisfaction, 0 score refers to dissatisfaction, 10 score refers to satisfaction. Higher scores mean a better outcome.

    Time frame: 48 hours postoperatively

  8. Nausea

    Using VRS (Verbal Rating Scales) to evaluate the degree of nausea. 0 score refers to comfort, 10 score refers to excruciating nause. Higher scores mean a worse outcome.

    Time frame: 4 hours postoperatively

  9. Nausea

    Using VRS (Verbal Rating Scales) to evaluate the degree of nausea. 0 score refers to comfort, 10 score refers to excruciating nause. Higher scores mean a worse outcome.

    Time frame: 8 hours postoperatively

  10. Nausea

    Using VRS (Verbal Rating Scales) to evaluate the degree of nausea. 0 score refers to comfort, 10 score refers to excruciating nause. Higher scores mean a worse outcome.

    Time frame: 24 hours postoperatively

  11. Nausea

    Using VRS (Verbal Rating Scales) to evaluate the degree of nausea. 0 score refers to comfort, 10 score refers to excruciating nause. Higher scores mean a worse outcome.

    Time frame: 48 hours postoperatively

  12. Nausea

    Using VRS (Verbal Rating Scales) to evaluate the degree of nausea. 0 score refers to comfort, 10 score refers to excruciating nause. Higher scores mean a worse outcome.

    Time frame: 72 hours postoperatively

  13. Sedation

    Using RSAS(Riker Sedation Agitation Scale) to evaluate the status of sedation. 1 score is not aroused, 2 score is very calm, 3 score is calm, 4 score is quiet cooperation, 5 is mildly agitated, 6 score was moderate agitation, and 7 score was severe agitation. Higher and lower scores both mean a worse outcome.

    Time frame: 4 hours postoperatively

  14. Sedation

    Using RSAS(Riker Sedation Agitation Scale) to evaluate the status of sedation. 1 score is not aroused, 2 score is very calm, 3 score is calm, 4 score is quiet cooperation, 5 is mildly agitated, 6 score was moderate agitation, and 7 score was severe agitation. Higher and lower scores both mean a worse outcome.

    Time frame: 8 hours postoperatively

  15. Sedation

    Using RSAS(Riker Sedation Agitation Scale) to evaluate the status of sedation. 1 score is not aroused, 2 score is very calm, 3 score is calm, 4 score is quiet cooperation, 5 is mildly agitated, 6 score was moderate agitation, and 7 score was severe agitation. Higher and lower scores both mean a worse outcome.

    Time frame: 24 hours postoperatively

  16. Sedation

    Using RSAS(Riker Sedation Agitation Scale) to evaluate the status of sedation. 1 score is not aroused, 2 score is very calm, 3 score is calm, 4 score is quiet cooperation, 5 is mildly agitated, 6 score was moderate agitation, and 7 score was severe agitation. Higher and lower scores both mean a worse outcome.

    Time frame: 48 hours postoperatively

  17. Sedation

    Using RSAS(Riker Sedation Agitation Scale) to evaluate the status of sedation. 1 score is not aroused, 2 score is very calm, 3 score is calm, 4 score is quiet cooperation, 5 is mildly agitated, 6 score was moderate agitation, and 7 score was severe agitation. Higher and lower scores both mean a worse outcome.

    Time frame: 72 hours postoperatively

  18. Vomiting

    the times of vomiting

    Time frame: 4 hours postoperatively

  19. Vomiting

    the times of vomiting

    Time frame: 8 hours postoperatively

  20. Vomiting

    the times of vomiting

    Time frame: 24 hours postoperatively

  21. Vomiting

    the times of vomiting

    Time frame: 48 hours postoperatively

  22. Vomiting

    the times of vomiting

    Time frame: 72 hours postoperatively

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05249153
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Sep 23, 2020
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 21, 2024

Study contacts

Yuguang Huang, MD
study chair · Anesthesiology of PUMCH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion